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ABSTRACT
Accurate and reproducible measurement of blood-brain barrier (BBB) integrity is critical in the
assessment of the pathophysiology of the central nervous system disorders and in monitoring
therapeutic effects. The widely-used low molecular weight marker [14C]sucrose is non-specific in
the absence of chromatographic separation. The purpose of this study was to develop and
validate a sensitive and reproducible LC-MS/MS method for the analysis of stable isotopemodified [13C12]sucrose in brain, plasma, and blood to determine BBB permeability to sucrose.
After addition of internal standard (IS, [13C6]sucrose), the marker and IS were recovered from
diluted rat blood, plasma, and brain homogenate by protein precipitation using acetonitrile. The
recovery of the marker and IS was almost quantitative (90-106%) for all three matrices. The
recovered samples were directly injected into an isocratic UPLC system with a run time of 6
min. Mass spectrometry was conducted using multiple reaction monitoring in negative mode.
The method was linear (r2 ≥ 0.99) in the concentration ranges tested for the diluted blood and
plasma (10–1000 ng/mL) and brain homogenate (1-200 ng/mL). The lower limit of quantitation
of the assay was 0.5 pg injected on column. The assay was validated (n = 5) based on acceptable
intra- and inter-run accuracy and precision values. The method was successfully used for the
measurement of serial blood and plasma and terminal brain concentrations of [13C12]sucrose after
a single intravenous does (10 mg/kg) of the marker to rats. As expected, the apparent brain
uptake clearance values of [13C12]sucrose were low in healthy rats. The method may be useful for
determination of the BBB integrity in animal models.

Keywords: Sucrose; Blood-brain barrier permeability; UPLC-MS/MS; Blood; Plasma; Brain
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1. Introduction
Measurement of the permeability of cellular barriers, in particular of vascular barriers,
requires the use of suitable markers. If the goal is to determine passive, diffusion mediated
permeability to small, drug like compounds, the choices are quite limited, because many small
molecules are substrates of one or more of a host of facilitative or active transport systems [1]. A
permeability of particular importance is the blood-brain barrier (BBB). The BBB is the
microvascular barrier that strictly controls the passage of endogenous and exogenous molecules
from blood to the central nervous system (CNS). It is formed by the endothelial cells of brain
microvessels, which feature complex tight junctions resulting in extremely low paracellular
permeability [2, 3]. Many acute and chronic diseases affecting the CNS are accompanied by a
compromised BBB [4]. Therefore, techniques to accurately and reproducibly measure BBB
integrity are critical tools in the assessment of the pathophysiology of CNS disorders and in
monitoring therapeutic effects.
The functional integrity of the BBB with respect to paracellular leakage is measured by
low molecular weight hydrophilic compounds or by macromolecular markers. Most of the toxic
substances that are believed to be associated with neurological complications (endogenous
metabolites including ammonia, bile acids, creatinine, and glutamine, and xenobiotics including
drugs) have molecular weights less than 1000 Da. Hence, low molecular weight markers of BBB
permeability are of particular interest. Notwithstanding, the most frequently used marker in the
BBB literature, the azo dye Evans blue (961 Da) [5], supposedly measures permeability to
macromolecules due to its tight binding to serum albumin. Evidence for binding to multiple
proteins other than albumin [6], and for potentially significant fractions of unbound dye [7]
raises doubts about the soundness of Evans blue based data. Another common small molecule
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dye is fluorescein (376 Da). That marker may be prone to artifacts, too, since it can interact with
efflux transporters present at the BBB [8]. Additionally, plasma protein binding of fluorescein
must not be neglected. We recently reported that the free fraction of fluorescein is significantly
increased by bile acids [9], leading to altered brain disposition of the marker in rat models of
Pringle maneuver and partial hepatectomy [10]. Changes in the free fraction of fluorescein
resulted in increased concentrations of fluorescein in the brain, without any significant changes
in actual BBB permeability [10].
Unlike fluorescein, plasma protein binding or affinity to any known mammalian
transporter does not affect the disaccharide sucrose (342 Da). It has long been established as a
reliable marker of extracellular fluid volume [11, 12]. Since initial applications in the 1960s and
1970s [13-15], radiolabeled sucrose (e.g., [14C]sucrose) is considered a reliable low molecular
weight, hydrophilic, poorly diffusible tracer for quantitative analysis of BBB integrity and has
been used in more than 500 publications [5]. However, radiotracer use is associated with special
handling and licensing requirements. Furthermore, with few exceptions radioactivity
measurement is performed on samples without prior chromatographic separation and is thus nonspecific. Even small impurities in the dosing solution might significantly impact the outcome of
such experiments [16, 17].
We propose that the advancement of new analytical methods, such as LC-MS/MS, should
enable the use of non-radioactive sucrose as marker of BBB permeability. In fact, tandem mass
spectrometry methods for measurement in body fluids of various sugars, including sucrose, have
recently been described [18-20]. It is obvious, however, that sucrose from dietary sources is
present in plasma of humans and animals at variable concentrations in the low micromolar range
[18, 21]. As a consequence natural [12C]sucrose cannot easily be utilized as a marker for the
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measurement of BBB permeability. Therefore, the purpose of the current study was to develop a
sensitive and reproducible LC-MS/MS method for the analysis of stable isotope-modified
[13C]sucrose in brain, plasma, and blood.

2. Materials and methods
2.1.Chemicals and reagents
We purchased [13C12]sucrose (all the carbons in both glucose and fructose molecules are
labeled with

13

C isotope; denoted

13

C-sucrose) and the internal standard (IS), which was

[13C6]sucrose (all the carbons in fructose molecule are labeled with 13C isotope), from Omicron
Biochemicals (South Hill Street South Bend, IN, USA). LC-MS grade water was purchased
under the brand name J.T. Baker from Avantor Performance Materials, Inc. (Center Valley, PA).
Analytical grade ammonium hydroxide and LC-MS grade acetonitrile were purchased from
Fisher Scientific (Fair Lawn, NJ). For anesthesia, ketamine and xylazine solutions were
purchased from Lloyd Laboratories (Shenandoah, IA, USA). Heparin solution was purchased
from APP Pharmaceuticals (Schaumburg, IL, USA). All other chemicals were UHPLC grade and
obtained from commercial sources.
2.2.Instrumentation
For mass spectrometry, we used an AB SCIEX QTRAP® 5500 mass spectrometer
(Foster City, CA, USA). Liquid chromatography was performed using a Nexera UPLC system
from Shimadzu Corporation (Columbia, MD). The UPLC system consisted of Sil-30AC
autosampler, LC-30AD pumps, a CBM-20A controller, a DGA-20A5 degasser, and a CTO-30A
column oven. For the acquisition of data and quantification, we used Analyst and Multi-Quant
software, respectively. Chromatographic separation was performed using an Acquity BEH amide
5

column with 3 mm x 50 mm dimensions and a 1.7 µm particle size, attached to an inline filter
with a pore size of 0.2 µm as a pre-column The isocratic mobile phase was acetonitrile: water:
ammonium hydroxide (72:28:0.1), v/v), run at a flow rate of 0.2 mL/min. Column temperature
was maintained at 45oC, and the autosampler was at room temperature. The total run time was 6
min. However MS data were collected from 1.5 to 5 min only, and the valve was diverted to
waste before and after that time.
2.3. Mass spectroscopy conditions
Analysis was performed by using a triple quadruple mass spectrometer to monitor the
m/z transitions with the help of the Analyst software connected to the system. The ionization
source was electrospray ionization with multiple reactions monitoring system in negative mode.
The mass spectrometer conditions were optimized to get optimum M-H-1 by continuous injection
of the standard solution with injection pump at a concentration of 100 ng/mL in a mixture of
acetonitrile and water (80:20). The optimized mass spectrometer parameters were as follows: ion
spray voltage, −4500 V; collision gas, high; curtain gas, 30 psi; temperature, 600 ◦C; ion source
gas 1 (nebulizer gas), 55 psi; and ion source gas 2 (turbo gas), 55 psi. The optimum transitions
for 13C-sucrose and IS were 353→92 m/z and 347→89 m/z, respectively.
2.4.Standard curve preparation
Stock solutions of 13C-sucrose as well as IS were made in water at a concentration of 10
mg/mL. Samples for standard curves were made in blank rat plasma, blood, or brain matrices.
For plasma and blood standard curves, blank rat plasma or blood was spiked with the 13C-sucrose
stock solutions in water to give concentrations of 1, 2, 5, 10, 25, 50, and 100 µg/mL for plasma
and 0.5, 1, 2, 5, 10, 25, and 50 µg/mL for blood. The plasma and blood calibration standards
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were then diluted 100 and 50 fold with water to produce concentrations of 10, 20, 50, 100, 250,
500, and 1000 ng/mL before being subjected to the sample preparation procedure detailed below.
The brain standards were prepared in blank brain homogenate, which was prepared by
homogenization of brain in water (1:9). Brain homogenates were spiked with the stock solution
of

13

C-sucrose to give concentrations of 1, 2, 4, 10, 50, 100, and of 200 ng/mL. Calibration

curves were constructed by plotting the ratio of peak areas for the analyte: IS versus the spiked
concentration of the analyte.
2.5.Sample preparation
As mentioned above, plasma and blood calibration standards and unknown samples were
diluted 100 and 50 times, respectively, with water, and brain samples were homogenized in
water (1:9) before analysis. Diluted plasma, blood, and undiluted brain homogenate samples
were used for analysis. For sample preparation, 180 µL of acetonitrile: water (80:20), containing
10 (for plasma or blood) or 2 (for brain) ng/mL of IS, were added to 20 µL of each sample in a
microcentrifuge tube. Samples were then vortex-mixed for 15 sec, centrifuged at 20,000 g (room
temperature) for 10 min, and the supernatant was transferred into autosampler inserts for
injection onto the column. The injection volume was 5 µL.
2.6.Method validation
The inter- and intra-run accuracies and precisions of the quality control samples were
evaluated against calibration curves. For the calculation, five repeats of low, middle, and high
concentrations

were

analyzed.

The

accuracy

was

calculated

by

measured

concentration*100/nominal concentration. Precision was calculated as a percent of relative
standard deviations (R.S.D.). The acceptable inter- and intra-run limits for the accuracy were set
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at 85–115% for the middle and high concentrations and 80–120% for the low concentration [22].
The acceptable precision values were 15% (middle and high concentrations) and 20% (low
concentration) [22].
2.7.Linearity
The linearity of calibration curves was evaluated by the coefficient of determination (r2)
of the linear regression analysis of the concentration-response data using a weight of 1/x, where x
is the concentration.
2.8.Recovery
The recovery of 13C-sucrose was calculated in diluted plasma and blood samples and in
brain homogenates. Five repeats of two concentrations from the calibration curve, 50 and 500
ng/mL for the plasma and blood or 10 and 100 ng/mL for the brain homogenate samples, were
used. Samples with equivalent concentrations prepared in water (instead of matrix) were used as
references. The samples and references were subjected to the Sample preparation method
described above, and the peak areas of

13

C-sucrose and IS were determined. Recovery was

calculated by using the following equation:
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =

𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒
×100
𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒

where Sample and Reference refer to the matrix and water, respectively.
2.9. Application of the method
The method was used to measure the plasma, blood, and brain concentrations of

13

C-

sucrose in rats after intravenous administration of the stable isotope. Additionally, the data were
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used to calculate the apparent brain uptake clearances (Kin) of 13C-sucrose as a measure of BBB
permeability [14]. The animal protocol used in this study was approved by our Institutional
Animal Care and Use Committee (IACUC). Adult, male Sprague-Dawley rats were purchased
from Charles River Laboratories, Inc. (Wilmington, MA, USA). Rats were kept in animal care
facility in 12 h day/night cycles with free access to food and water for 2-3 days. After an
overnight fast, rats (n = 3) were anesthetized with an intramuscular injection of ketamine:
xylazine (80:8 mg/kg), and catheters were placed in their penile vein and femoral artery for
dosing and blood collection, respectively. 13C-sucrose, at a dose of 10 mg/kg, was injected as a
bolus dose into the penile vein, and serial blood samples were collected in heparinized
microcentrifuge tubes at 0 (just before injection), 1, 5, 10, 15, 20, and 30 min. An aliquot (20 µL)
of blood was kept for blood 13C-sucrose concentration measurement, and the remaining volume
was centrifuged at room temperature for 5 min at a speed of 14,000 g to separate plasma. At the
end of 30 min, rat whole body was perfused with ice-cold saline for 5 min at a rate of 25
mL/min. Additionally, both jugular veins were cut to assure the lack of blood in the outflow
solution, indicating complete washout of the residual blood in the brain. Brain was then collected
and snap frozen in cold iso-pentane. Brain and water-diluted blood (50 fold) and plasma (100
fold) were kept at -80ᴼC until subjected to the analysis method described above. Apparent Kin
values were calculated using the following equations [23, 24]:
!"##$
𝐾!"

!"
𝐶!"
=
!!!"
𝐴𝑈𝐶!"##$

!"#$%#
𝐾!"

!"
𝐶!"
=
!!!"
𝐴𝑈𝐶!"#$%#
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!"#$%#
!"##$
!!!"
where 𝐾!"
and 𝐾!"
are the Kin values based on the blood (𝐴𝑈𝐶!"##$
) and plasma
!!!"
(𝐴𝑈𝐶!"#$%#
) area under the sucrose concentration-time curves from time zero to 30 min,

respectively. The AUC values were determined by trapezoidal rule.

3. Results
3.1.LC-MS/MS data
Figure 1 depicts the chromatograms of brain, blood, and plasma matrices for blank
samples (A), lowest

13

C-sucrose standards in the calibration curves (B), and the lowest

concentrations of 13C-sucrose observed in the samples at 30 min after a single 10-mg/kg dose of
13

C-sucrose (C). Also depicted in Fig. 1 are the chromatograms of IS (D). Under the

chromatographic conditions used in our studies, the analyte (13C-sucrose) and IS eluted at 2.4-2.6
min as sharp peaks with low baseline noises without any interference from any of the matrices.
3.2.Recovery
Recoveries of 13C-sucrose and IS from the plasma, blood, and brain samples at a low and
a high concentration in the calibration curves are presented in the Table 1. The recoveries of 13Csucrose and IS at both concentrations were relatively high (≥ 90%), and in most cases
quantitative, in all the tested matrices.
3.3.Linearity
Calibration curves constructed in the ranges of 10-1000 ng/mL (diluted plasma or blood)
and 1-200 ng/mL (brain homogenate) were linear as the r2 values were ≥ 0.99 for all the matrices
and the inter- and intra run calibration curves. The representative equations for the plasma,
blood, and brain standard curves were y = 0.00820 x – 0.00385 (r2= 0.999), y = 0.0125 x –
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0.00475 (r2 = 0.998), and y = 0.0370 x – 0.0165 (r2 = 0.998), where y and x refer to the

13

C-

sucrose: IS peak area ratios and the concentrations of 13C-sucrose, respectively.
3.4.Inter- and intra-run accuracy and precision
Table 2 shows the summary of accuracy and precisions values. The inter- and intra-run
accuracy and precision values were within the limits of the FDA guidelines for the method
validation. The accuracy was within 94.7-106% for all the tested concentrations and matrices
(Table 2). Additionally, samples precision values (R.S.D) were ≤ 11%, for all the various
concentrations and matrices (Table 2).
3.5.LLOD and LLOQ
As demonstrated in Table 2 and Fig. 1B, we were able to accurately and precisely
quantify the lowest concentrations of 13C-sucrose in the calibration curves of blood or plasma (10
ng/mL) and brain homogenate (1 ng/mL). The brain homogenate concentration of 1 ng/mL is
equivalent to injection of 0.5 pg of the analyte on the column. Therefore, the LLOQ for the assay
is 0.5 pg. However, based on a signal to noise ratio of ≥ 3, the LLOD of the assay is 0.1 pg.
3.6.Application of the method
The developed method was applied to estimate the plasma, blood, and brain
concentrations of 13C-sucrose after injection of a single intravenous bolus dose (10 mg/kg) of the
marker to rats. The plasma and blood concentration-time profiles (A), plasma and blood AUC
(B), brain concentrations (C), and apparent brain Kin values (D) of
presented in Fig. 2.

13

13

C-sucrose in rats are

C-sucrose showed a multiexponential decline in both blood and plasma

(Fig. 2A), with blood AUCs comprising 62% of the plasma AUCs (Fig. 2B). The average (± SD)
values of the terminal brain concentration of

13

C-sucrose at 30 min was 43.4 ± 3.03 ng/g (Fig.
11

2C), resulting in the blood and plasma Kin values of 0.058 ± 0.004 and 0.095 ± 0.011 µL/(min.g),
respectively (Fig. 2D).

4. Discussion
The results of our study indicate the following: (i) a specific LC-MS/MS method could be
developed, which allows accurate quantification of [13C12]sucrose in brain, plasma and blood
samples; (ii) the measurement is highly sensitive and reproducible; (iii) the LC-MS/MS based
method presents an alternative to techniques based on radiolabeled tracers for permeability
measurements.
In a pilot series of detector experiments, we used electrospray ionization and negative ion
detection mode to optimize the detection method and sensitivity of the assay. The mass
spectrometer conditions were optimized by continuous injection of the standard solution with
injection pump to get the optimum M-H-1. In the continuous scanning mode, most robust m/z
values for [13C12]sucrose were found at 92, 61, and 89. However, after running with mobile
phase and column, the best signal to noise ratio was obtained at a m/z of 92. Therefore, the m/z
transition of 353→92 was selected for our LC-MS/MS analysis. Additionally, the selected
transition for [13C6]sucrose (IS) was 347→89.
In our studies, we used a BEH amide column for the chromatographic separation, which
gives highly efficient separation of carbohydrates [25, 26]. We used an isocratic condition, at a
flow rate of 0.2 mL/min, which resulted in the elution of sucrose at ~2.5 min retention time after
a 5 µL sample injection volume. Our optimization studies indicated that the selection of mobile
phase is very important as higher contents of water in the mobile phase caused a significant
decrease in the sensitivity and much broader peaks. The optimum sensitivity and retention time
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were obtained with 0.1% ammonium hydroxide in a mixture of acetonitrile and water (72:28)
(Fig. 1).
Recovery of the analyte depends on the procedure used to clean up the samples from the
respective matrices. Deproteinization is one of the efficient methods for separation of low
molecular weight hydrophilic compounds, where acetonitrile or other organic solvents are used
alone or in combination with water [27]. We found a mixture of acetonitrile and water (80:20)
for protein precipitation to get satisfactory recovery (≥ 90%) from brain, plasma, and blood
(Table 1). In contrast, the use of 100% acetonitrile for protein precipitation resulted in
significantly lower sucrose recovery from the samples.
Previous reports also used a mixture of acetonitrile: water for precipitation of plasma
proteins in the assay of natural sucrose in the serum of bottlenose dolphins [20] and horses [18].
However, both of these methods used an acetonitrile: water ratio of 90:10, instead of 80:20 used
in our assay. Although the use of 90:10 ratio resulted in appropriate recoveries for the plasma
and blood samples, the recovery was not quantitative for the brain homogenate in our studies.
We also examined the effects of the ratio of water to brain tissue during the
homogenization of the brain on the recovery of the analyte and IS and/or brain matrix effect. As
demonstrated in Table 2, using a ratio of 9:1 (water: brain tissue) and an acetonitrile: water ratio
of 80:20 for protein precipitation resulted in a quantitative recovery of the analyte and IS from
the brain without any matrix effect. However, lower water ratios for preparation of the brain
homogenates resulted in lower recoveries and/or significant matrix effect (data not shown). The
high and almost quantitative recovery of the analyte and IS from all matrices (Table 2) also is an
indication of a lack of matrix effect using our sample preparation method.

13

Applying the m/z transitions outlined above, there was no substance peak in blank
samples of blood, plasma, or brain tissue at the retention time of sucrose (Fig. 1A). Undetectable
basal levels of [13C6]sucrose and [13C12]sucrose are expected in naïve samples due to the low
natural isotopic abundance of

13

C, which is 1.1%. Therefore, natural sucrose contains

[13C6]sucrose and [13C12]sucrose in fractions of about 1.8 x 10-12 and 3.1 x 10-24, respectively.
The developed LC-MS/MS method was successfully applied to measurements of the
blood, plasma, and brain concentrations of 13C-sucrose after injection of the marker to rats at a
dose of 10 mg/kg. The biexponential decline in the blood or plasma concentrations of
sucrose (Fig. 2 A) was similar to the profile previously reported for

14

13

C-

C-sucrose [28, 29].

Additionally, the blood AUC was 62% of plasma AUC (Fig. 2B), which is in agreement with the
lack of distribution of sucrose into red blood cells [11]. As expected from the

14

C-sucrose data

[15], the concentrations of 13C-sucrose in the brain were very low (Fig. 2C), relative to those in
the blood or plasma (Fig. 2A), indicating the relative impermeability of the intact BBB to
sucrose. The apparent brain uptake clearance of

13

C-sucrose (Fig. 2D), was lower than that

previously reported for 14C-sucrose [14, 15], which may be due to the lack of specificity of the
radioactivity measurement for the latter. Indeed, previous studies [17] have shown that the Kin
values obtained from

14

C-sucrose is significantly affected by the degree of impurities in the

injected 14C-sucrose.

5. Conclusions
In conclusion, a specific and sensitive LC-MS/MS method was developed for the
measurement of

13

measurement of

13

C-sucrose in biological samples. The method was successfully applied to

C-sucrose in blood, plasma, and brain after a single intravenous dose (10

14

mg/kg) of the marker to rats. The method may be useful for determination of the blood-brain
barrier integrity in normal and pathophysiologic conditions.
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Table1
Recoveries (mean ± SD) of

13

C-sucrose and internal standard from plasma, blood, and brain

samples at low and high concentrations in their respective calibration curves (n = 5).
Concentration
(ng/mL)

Recovery (%)
13

C-Sucrose

IS

Plasma
50

98.8 ± 0.5

90.0 ± 0.8

500

106 ± 4.7

98.7 ± 1.3

50

100 ± 2

94.1 ± 0.8

500

105 ± 2

101 ± 2.5

10

94.0 ± 2.2

97.7 ± 2.5

100

100 ± 1

96.3 ± 2.6

Blood

Brain Homogenate
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Table 2
Intra- and inter-run accuracy and precision values of the lowest, middle, and highest
concentrations of 13C-sucrose in standard curves for plasma, blood, and brain (n = 5).
Concentration
(ng/mL)

Intra-run

Inter-run

Accuracy

R.S.D. (%)

Accuracy

R.S.D. (%)

10

94.7

2.8

99.9

6.1

100

104

3.1

103

1.9

1000

102

1.8

98.1

2.5

10

98.6

2.9

104

8.2

100

101

3.3

95.4

2.0

1000

102

2.1

97.3

2.6

1

106

3.9

99.7

10.2

20

105

1.3

98.5

7.0

200

95.8

2.6

98.0

2.8

Diluted plasma

Diluted blood

Brain homogenate
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Legend for Figures
Fig. 1. Representative chromatograms of blank (A), lowest

13

C-sucrose concentration in the

calibration curves (B), 13C-sucrose in rat samples at 30 min after a single 10 mg/kg dose of the
marker (C), and internal standard (D). Left, middle, and right panels represent brain, blood, and
plasma chromatograms, respectively. The lowest standard curve sample for the brain contained 1
ng/mL and for the blood and plasma contained 10 ng/mL of 13C-sucrose.
Fig. 2. Plasma and blood concentration time profiles (A), plasma and blood AUCs (B), brain
concentrations (C), and apparent Kin values (D) of

13

C-sucrose. Rats (n = 3) were injected

intravenously with 10 mg/kg of the marker, and serial blood/plasma samples were collected for
30 min. Additionally, brain was collected at 30 min.
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